Cover image of the article: Comparing Ceftriaxone and Cefazolin for Treatment of Adult Acute Pyelonephritis; A Clinical Trial

Image Credit:Arch Clin Infect Dis

Comparing Ceftriaxone and Cefazolin for Treatment of Adult Acute Pyelonephritis; A Clinical Trial

Authors

Azadeh Ebrahimzadeh1, Seyed Alireza SaadatjooSeyed Alireza Saadatjoo ORCID2,*, Azadeh Alipoor Tabrizi1
1Department of Internal Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, IR Iran
2Faculty of Nursing and Midwifery, Birjand University of Medical Sciences, Birjand, IR Iran
*Corresponding Author: Faculty of Nursing and Midwifery, Birjand University of Medical Sciences, Birjand, Iran., s_saadatjoo@yahoo.com. Email: s_saadatjoo@yahoo.com

Archives of Clinical Infectious Diseases:Vol. 5, issue 2; 75-9
Published online:Apr 30, 2010
Article type:Research Article
How to Cite:Ebrahimzadeh A, Saadatjoo SA, Alipoor Tabrizi A. Comparing Ceftriaxone and Cefazolin for Treatment of Adult Acute Pyelonephritis; A Clinical Trial. Arch Clin Infect Dis. 2010;5(2):. doi:

Abstract

Background:

Urinary tract infection (UTI) is a major health concern worldwide. The present study was aimed to compare drug resistance to ceftriaxone and cefazolin in adult patients with acute pyelonephritis.

Patients and Methods:

For this clinical trial, patients with fever plus either dysuria, frequency, flank pain or flank tenderness were enrolled. Having performed urinalysis (U/A), urine culture (U/C) and antibiogram, they were randomly assigned in two groups: ceftriaxone 1gr twice a day or cefazolin 1gr trice a day. Three days later, urine was re-evaluated and patients were categorized as clinical and microbiological responders. Chi-square test and Fishers exact tests were used, when appropriate. Statistical significance was defined as p<0.05.

Results:

Study population included 59 females and 27 males. Escherichia coli was the most frequent isolated pathogen (86.0%). Dysuria, flank pain and flank tenderness was more frequent among non-E. coli-infected than E. coli-infected subjects, however, the difference was solely significant for flank tenderness (p=0.008). Clinical response was observed in 86.1%, 11.6%, and 2.3% of patients 3, 4, and 5 days following the therapy, respectively, however, there was no significant difference between ceftriaxone and cefazolin group. Totally, 93% of patients became culture negative. Rate of microbiological response did not differ significantly between groups.

Conclusion:

The results demonstrated that clinical and microbiological responses of patients with acute pyelonephritis are not always compatible. Meanwhile, first and third generation cephalosporins have similar efficacy for treatment of uncomplicated patients.

Highlights

Full Text

Full text is available in PDF

Copyright

© 2010, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

30
Aug
2002
Comparison of efficacy of oral ciprofloxacin versus IV eftriaxone in acute uncomplicated pyelonephritis

Comparison of efficacy of oral ciprofloxacin versus IV eftriaxone in acute uncomplicated pyelonephritis

Hamid Ziae,
ShahRokh Mosavi,
Raheb Ghorbani

Ziae H, Mosavi S, Ghorbani R. Comparison of efficacy of oral ciprofloxacin versus IV eftriaxone in acute uncomplicated pyelonephritis. koomesh. 2002;4(1):e151969. doi:

8
Oct
2024
The Impact of Antibiotic Prophylaxis with Cefazolin, and Ceftizoxime Along with Aminoglycosides on Postoperative Complications, Hospitalization, and Returning to Normal Life for Percutaneous Nephrolithotomy, a Prospective Cross-Sectional Study

The Impact of Antibiotic Prophylaxis with Cefazolin, and Ceftizoxime Along with Aminoglycosides on Postoperative Complications, Hospitalization, and Returning to Normal Life for Percutaneous Nephrolithotomy, a Prospective Cross-Sectional Study

Siavash Falahatkar,
Gholamreza Mokhtari,
Ehsan Kazemnezhad Leyli,
Milad Abed-Kamalchi,
Samira Kazemi,
Fatemeh Sheikhi
,et al.

Falahatkar S, Mokhtari G, Kazemnezhad Leyli E, Abed-Kamalchi M, Kazemi S, et al. The Impact of Antibiotic Prophylaxis with Cefazolin, and Ceftizoxime Along with Aminoglycosides on Postoperative Complications, Hospitalization, and Returning to Normal Life for Percutaneous Nephrolithotomy, a Prospective Cross-Sectional Study. Nephro-Urol Mon. 2024;16(4):e148503. doi: https://doi.org/10.5812/numonthly-148503

30
Apr
2010
Comparison of 3-Day and 7-Day Ciprofloxacin Regimen for the Treatment of Uncomplicated Urinary Tract Infection in Women:A Randomized Double-Blind Clinical Trial

Comparison of 3-Day and 7-Day Ciprofloxacin Regimen for the Treatment of Uncomplicated Urinary Tract Infection in Women:A Randomized Double-Blind Clinical Trial

Bahman Haghighi,
Hyaide Oskuilar,
Omid Nejadi,
Noushin Etesam,
Hamid Mostafavi

Haghighi B, Oskuilar H, Nejadi O, Etesam N, Mostafavi H. Comparison of 3-Day and 7-Day Ciprofloxacin Regimen for the Treatment of Uncomplicated Urinary Tract Infection in Women:A Randomized Double-Blind Clinical Trial. Arch Clin Infect Dis. 2010;5(2):. doi:

31
Jan
2009
Emergence of Cefepime Resistance in Gram-Negative Induced Nosocomial Infections

Emergence of Cefepime Resistance in Gram-Negative Induced Nosocomial Infections

Farzin Khorvash,
Kamyar Mostafavizadeh,
Sina Mobasherizadeh,
Mohaddeseh Behjati,
Mansoor Salehi

Khorvash F, Mostafavizadeh K, Mobasherizadeh S, Behjati M, Salehi M. Emergence of Cefepime Resistance in Gram-Negative Induced Nosocomial Infections. Arch Clin Infect Dis. 2009;4(1):. doi:

28
Sep
2013
Ceftriaxone–Associated Nephrolithiasis in Children

Ceftriaxone–Associated Nephrolithiasis in Children

Azita Fesharakinia,
Ali-Reza Ehsanbakhsh,
Nasrin Ghorashadizadeh

Fesharakinia A, Ehsanbakhsh A, Ghorashadizadeh N. Ceftriaxone–Associated Nephrolithiasis in Children. Inn J Pediatr. 2013;23(6):. doi:

More by these authors

Azadeh EbrahimzadehPubMedScholar
Seyed Alireza SaadatjooPubMedScholar
Azadeh Alipoor TabriziPubMedScholar
Share
Cited by
Metrics